
NASDAQHealthcareBiotechnology
最新資料
US$49.55
−US$3.86 · -7.23%
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
前收盤價
US$49.55
−US$3.86 · -7.23%
盤中時間採用ET。市場資料可能有所延遲。
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
日內區間
目前US$49.55
52週區間
目前US$49.55
盤中時間採用ET。市場資料可能有所延遲。
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
日內區間
目前US$49.55
52週區間
目前US$49.55
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 銷貨成本 | 24.8萬 USD | — | — | — |
| 毛利 | −24.8萬 USD | — | — | — |
| 研究與開發 | 7915.9萬 USD | 5741.5萬 USD | 2853.4萬 USD | 2139.7萬 USD |
| 銷售、一般及管理費用 | 1889.6萬 USD | 1077.9萬 USD | 677.7萬 USD | 376.4萬 USD |
| 營業費用 | 9805.5萬 USD | 6819.4萬 USD | 3531.1萬 USD | 2516.1萬 USD |
| 利息收入 | 1108.4萬 USD | 627.2萬 USD | 274.8萬 USD | 37.2萬 USD |
| 利息支出 | — | — | — | 37.4萬 USD |
| 折舊和攤銷 | 24.8萬 USD | 24.4萬 USD | 15.7萬 USD | 5.6萬 USD |
| 營業利益 | −9805.5萬 USD | −6819.4萬 USD | −3531.1萬 USD | −2516.1萬 USD |
| 淨利 | −8697.1萬 USD | −6192.2萬 USD | −3256.3萬 USD | −2613.5萬 USD |
公司資料更新於 2026年11月22日。
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI4757.78萬0.00%6893億 USD0.03%US$340.02-3.52%
iShares Russell 2000 ETFIWM4148.65萬0.06%715.37億 USD0.19%US$256.61-2.88%
Vanguard Extended Market ETFVXF1897.71萬0.02%302億 USD0.05%US$211.44-3.21%
iShares Russell 2000 Growth ETFIWO1559.8萬0.12%127.32億 USD0.24%US$320.43-3.57%
iShares Biotechnology ETFIBB1171.31萬0.11%105.27億 USD0.44%US$199.54-2.05%
Vanguard Russell 2000 ETFVTWO1019.57萬0.06%168億 USD0.06%US$103.76-2.76%
State Street SPDR S&P Pharmaceuticals ETFXPH914.21萬1.82%5.01億 USD0.35%US$62.15-2.00%
Schwab U.S. Small-Cap ETFSCHA829.45萬0.04%204.47億 USD0.03%US$30.51-2.83%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
iShares Biotechnology ETFIBB
Vanguard Russell 2000 ETFVTWO
State Street SPDR S&P Pharmaceuticals ETFXPH
Schwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。